Log in

NASDAQ:XOMA - XOMA Stock Price, Forecast & News

-1.05 (-3.66 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
Now: $27.66
50-Day Range
MA: $25.10
52-Week Range
Now: $27.66
Volume26,714 shs
Average Volume47,044 shs
Market Capitalization$242.03 million
P/E RatioN/A
Dividend YieldN/A
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:XOMA



Sales & Book Value

Annual Sales$5.30 million
Book Value$2.24 per share


Net Income$-13,340,000.00


Market Cap$242.03 million
Next Earnings Date3/5/2020 (Estimated)
OptionableNot Optionable

Receive XOMA News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

XOMA (NASDAQ:XOMA) Frequently Asked Questions

What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

How were XOMA's earnings last quarter?

XOMA Corp (NASDAQ:XOMA) posted its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported $0.20 earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.48) by $0.68. The biotechnology company had revenue of $8.86 million for the quarter. XOMA had a negative return on equity of 8.93% and a negative net margin of 10.19%. View XOMA's Earnings History.

When is XOMA's next earnings date?

XOMA is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for XOMA.

What price target have analysts set for XOMA?

2 analysts have issued 12-month price targets for XOMA's shares. Their forecasts range from $25.00 to $30.00. On average, they anticipate XOMA's share price to reach $27.50 in the next year. This suggests that the stock has a possible downside of 0.6%. View Analyst Price Targets for XOMA.

What is the consensus analysts' recommendation for XOMA?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for XOMA.

What are Wall Street analysts saying about XOMA stock?

Here are some recent quotes from research analysts about XOMA stock:
  • 1. According to Zacks Investment Research, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. " (2/22/2020)
  • 2. HC Wainwright analysts commented, "We project U.S. peak sales of $325M in 2026 for DSUVIA. For Zalviso, we project product launch in 1H20 (85% POS) with peak sales in 2027 of about $185M. We apply a 12.5% discount rate to both products." (4/12/2019)

Has XOMA been receiving favorable news coverage?

News coverage about XOMA stock has been trending negative on Saturday, according to InfoTrie. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. XOMA earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for XOMA.

Are investors shorting XOMA?

XOMA saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 542,100 shares, an increase of 32.3% from the January 15th total of 409,700 shares. Based on an average daily volume of 75,600 shares, the short-interest ratio is presently 7.2 days. Approximately 6.7% of the company's stock are short sold. View XOMA's Current Options Chain.

Who are some of XOMA's key competitors?

What other stocks do shareholders of XOMA own?

Who are XOMA's key executives?

XOMA's management team includes the folowing people:
  • Mr. James R. Neal, CEO & Director (Age 63)
  • Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 45)
  • Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 43)
  • Dr. Deepshikha Datta, Chief Bus. Officer

Who are XOMA's major shareholders?

XOMA's stock is owned by many different of institutional and retail investors. Top institutional investors include BVF Inc. IL (30.19%), Renaissance Technologies LLC (1.03%), Geode Capital Management LLC (0.72%), Credit Suisse AG (0.62%), Bank of New York Mellon Corp (0.52%) and Marshall Wace LLP (0.51%). Company insiders that own XOMA stock include Bvf Partners L P/Il, James R Neal, Ness W Denman Van, Thomas M Burns and Value Fund L P Biotechnology. View Institutional Ownership Trends for XOMA.

Which institutional investors are selling XOMA stock?

XOMA stock was sold by a variety of institutional investors in the last quarter, including AXA. Company insiders that have sold XOMA company stock in the last year include James R Neal, Ness W Denman Van and Thomas M Burns. View Insider Buying and Selling for XOMA.

Which institutional investors are buying XOMA stock?

XOMA stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Renaissance Technologies LLC, Credit Suisse AG, Marshall Wace LLP, EAM Investors LLC, Laurion Capital Management LP, Goldman Sachs Group Inc. and Geode Capital Management LLC. Company insiders that have bought XOMA stock in the last two years include Bvf Partners L P/Il, James R Neal and Value Fund L P Biotechnology. View Insider Buying and Selling for XOMA.

How do I buy shares of XOMA?

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is XOMA's stock price today?

One share of XOMA stock can currently be purchased for approximately $27.66.

How big of a company is XOMA?

XOMA has a market capitalization of $242.03 million and generates $5.30 million in revenue each year. The biotechnology company earns $-13,340,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. XOMA employs 11 workers across the globe.View Additional Information About XOMA.

What is XOMA's official website?

The official website for XOMA is http://www.xoma.com/.

How can I contact XOMA?

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected]

MarketBeat Community Rating for XOMA (NASDAQ XOMA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  398 (Vote Outperform)
Underperform Votes:  394 (Vote Underperform)
Total Votes:  792
MarketBeat's community ratings are surveys of what our community members think about XOMA and other stocks. Vote "Outperform" if you believe XOMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XOMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel